OPTIMUM: Early Outcomes From a Prospective Registry of PCI in Patients at Prohibitive Risk for CABG

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Equity/Stock(s)/Options (Personal) - Biostar Ventures
• Grant Support/Research Contract (Institutional) - Medtronic; Teleflex; Abbott Vascular; CSI; Biotronik
• Consultant Fee/Honoraria/Speaker's Bureau (Personal) - CSI